Israeli Medtech UltraSight Raises $24 Million for US Expansion
Israeli medical technology company UltraSight has raised $24 million in Series B2 financing to expand its AI guided cardiac ultrasound technology in the United States.
The investors
The round was announced on September 23 and led by Alive HealthTech Growth Fund.
Other participants included Deep Insight, Star51 Capital, Connecticut Innovations and eHealth Ventures.
Guidance, not diagnosis
UltraSight develops artificial intelligence software designed to guide medical professionals while they acquire ultrasound images of the heart.
The distinction between acquisition and diagnosis is important.
UltraSight's software assists the person holding the ultrasound probe by providing real time guidance about its position and orientation. The resulting images still form part of a clinical workflow involving qualified medical professionals.
FDA clearance and plans
The US Food and Drug Administration database confirms clearance for UltraSight Guidance under 510(k) number K251416. The system is intended to assist medical professionals other than expert sonographers in acquiring standard two dimensional transthoracic echocardiography views in adult patients.
The company also has an earlier clearance dating to 2023.
UltraSight says the new capital will support commercial expansion across US healthcare systems as well as development of additional workflows for intensive care and circulatory support settings.
Why it matters
Cardiac ultrasound is widely used because it can provide clinicians with rapid information about heart structure and function without exposing patients to ionizing radiation.
One limiting factor is the expertise required to acquire consistently useful images.
AI guidance systems are being developed partly to reduce that bottleneck by helping more trained healthcare personnel capture standardized views.
Whether that ultimately changes staffing requirements or patient outcomes will depend on deployment data and clinical evidence.
For Israel's health technology sector, however, the financing represents the movement of another locally developed AI system from research and regulatory clearance toward broader commercial deployment.
